These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 27788301)

  • 1. Prasugrel Use Following PCI and Associated Patient Outcomes: Insights From the National VA CART Program.
    Aggarwal V; Armstrong EJ; Liu W; Maddox TM; Ho PM; Carey E; Wang T; Sherwood M; Tsai TT; Rumsfeld JS; Bradley SM
    Clin Cardiol; 2016 Oct; 39(10):578-584. PubMed ID: 27788301
    [TBL] [Abstract][Full Text] [Related]  

  • 2. "Real-World" Comparison of Prasugrel With Ticagrelor in Patients With Acute Coronary Syndrome Treated With Percutaneous Coronary Intervention in the United States.
    Larmore C; Effron MB; Molife C; DeKoven M; Zhu Y; Lu J; Karkare S; Lieu HD; Lee WC; Vetrovec GW
    Catheter Cardiovasc Interv; 2016 Oct; 88(4):535-544. PubMed ID: 26577386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations Between Chronic Kidney Disease and Outcomes With Use of Prasugrel Versus Clopidogrel in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: A Report From the PROMETHEUS Study.
    Baber U; Chandrasekhar J; Sartori S; Aquino M; Kini AS; Kapadia S; Weintraub W; Muhlestein JB; Vogel B; Faggioni M; Farhan S; Weiss S; Strauss C; Toma C; DeFranco A; Baker BA; Keller S; Effron MB; Henry TD; Rao S; Pocock S; Dangas G; Mehran R
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2017-2025. PubMed ID: 28780028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Access Site on Bleeding and Ischemic Events in Patients With Non-ST-Segment Elevation Myocardial Infarction Treated With Prasugrel: The ACCOAST Access Substudy.
    Porto I; Bolognese L; Dudek D; Goldstein P; Hamm C; Tanguay JF; Ten Berg J; Widimský P; Le Gall N; Zagar AJ; LeNarz LA; Miller D; Montalescot G;
    JACC Cardiovasc Interv; 2016 May; 9(9):897-907. PubMed ID: 27151605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of reduced-dose prasugrel vs. standard-dose clopidogrel on in-hospital outcomes of percutaneous coronary intervention in 62 737 patients with acute coronary syndromes: a nationwide registry study in Japan.
    Akita K; Inohara T; Yamaji K; Kohsaka S; Numasawa Y; Ishii H; Amano T; Kadota K; Nakamura M; Maekawa Y
    Eur Heart J Cardiovasc Pharmacother; 2020 Jul; 6(4):231-238. PubMed ID: 31593213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: Insights from the TRANSLATE-ACS study.
    Effron MB; Wang TY; Fonarow GC; Henry TD; Zettler ME; Baker BA; McCoy LA; Peterson ED
    Catheter Cardiovasc Interv; 2018 Feb; 91(2):242-250. PubMed ID: 28988425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prasugrel (Efient®) with percutaneous coronary intervention for treating acute coronary syndromes (review of TA182): systematic review and economic analysis.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Fleeman N; McEntee J; Dundar Y; Richardson M; Fisher M
    Health Technol Assess; 2015 Apr; 19(29):1-130. PubMed ID: 25896573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post percutaneous coronary interventional adverse cardiovascular outcomes and bleeding events observed with prasugrel versus clopidogrel: direct comparison through a meta-analysis.
    Bundhun PK; Huang F
    BMC Cardiovasc Disord; 2018 May; 18(1):78. PubMed ID: 29720092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of Prasugrel and Ticagrelor in Stable Ischemic Heart Disease After Percutaneous Coronary Intervention, 2009-2016.
    Dayoub EJ; Nathan AS; Khatana SAM; Seigerman M; Tuteja S; Kobayashi T; Kolansky DM; Groeneveld PW; Giri J
    Circ Cardiovasc Interv; 2019 Jan; 12(1):e007434. PubMed ID: 30608869
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of Contraindicated Antiplatelet Medications in the Setting of Percutaneous Coronary Intervention: Insights From the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program.
    Barnes GD; Stanislawski MA; Liu W; Barón AE; Armstrong EJ; Ho PM; Klein A; Maddox TM; Nallamothu BK; Rumsfeld JS; Tsai TT; Bradley SM
    Circ Cardiovasc Qual Outcomes; 2016 Jul; 9(4):406-13. PubMed ID: 27245070
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of Prasugrel Loading Doses in Patients Pre-Loaded With Clopidogrel in the Setting of Primary Percutaneous Coronary Intervention: Results of a Nonrandomized Observational Study.
    Räber L; Klingenberg R; Heg D; Kelbæk H; Roffi M; Tüller D; Baumbach A; Zanchin T; Carballo D; Ostojic M; Stefanini GG; Rodondi N; von Birgelen C; Moschovitis A; Engstrøm T; Gencer B; Auer R; Meier B; Mach F; Lüscher TF; Jüni P; Matter CM; Windecker S;
    JACC Cardiovasc Interv; 2015 Jul; 8(8):1064-1074. PubMed ID: 26205445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes.
    Faggioni M; Baber U; Chandrasekhar J; Sartori S; Weintraub W; Rao SV; Vogel B; Claessen B; Kini A; Effron M; Ge Z; Keller S; Strauss C; Snyder C; Toma C; Weiss S; Aquino M; Baker B; Defranco A; Bansilal S; Muhlestein B; Kapadia S; Pocock S; Poddar KL; Henry TD; Mehran R
    Catheter Cardiovasc Interv; 2019 Jul; 94(1):53-60. PubMed ID: 30656812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Associations Between Complex PCI and Prasugrel or Clopidogrel Use in Patients With Acute Coronary Syndrome Who Undergo PCI: From the PROMETHEUS Study.
    Chandrasekhar J; Baber U; Sartori S; Aquino M; Kini AS; Rao S; Weintraub W; Henry TD; Farhan S; Vogel B; Sorrentino S; Ge Z; Kapadia S; Muhlestein JB; Weiss S; Strauss C; Toma C; DeFranco A; Effron MB; Keller S; Baker BA; Pocock S; Dangas G; Mehran R
    Can J Cardiol; 2018 Mar; 34(3):319-329. PubMed ID: 29475531
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparing prasugrel to twice daily clopidogrel post percutaneous coronary intervention in a Veterans Affairs population.
    Khatri S; Pierce T
    Am J Health Syst Pharm; 2015 Sep; 72(17 Suppl 2):S98-S103. PubMed ID: 26272900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world observations with prasugrel compared to clopidogrel in acute coronary syndrome patients treated with percutaneous coronary intervention in the United States.
    Bae JP; Faries DE; Ernst FR; Lipkin C; Zhao Z; Moretz C; Lieu HD; Effron MB
    Curr Med Res Opin; 2014 Nov; 30(11):2207-16. PubMed ID: 25034466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world clopidogrel utilization in acute coronary syndromes: patients selection and outcomes in a single-center experience.
    Castini D; Persampieri S; Cazzaniga S; Ferrante G; Centola M; Lucreziotti S; Salerno-Uriarte D; Sponzilli C; Carugo S
    Ther Adv Cardiovasc Dis; 2017 Dec; 11(12):323-331. PubMed ID: 29134853
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of prasugrel and clopidogrel-treated patients with acute coronary syndrome undergoing percutaneous coronary intervention: A propensity score-matched analysis of the Acute Myocardial Infarction in Switzerland (AMIS)-Plus Registry.
    Kurz DJ; Radovanovic D; Seifert B; Bernheim AM; Roffi M; Pedrazzini G; Windecker S; Erne P; Eberli FR
    Eur Heart J Acute Cardiovasc Care; 2016 Feb; 5(1):13-22. PubMed ID: 25614494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial.
    Sibbing D; Aradi D; Jacobshagen C; Gross L; Trenk D; Geisler T; Orban M; Gori T; Hadamitzky M; Merkely B; Kiss RG; Komócsi A; Dézsi CA; Thalmeier A; Löw A; Holdt L; Teupser D; Ince H; Felix SB; Parma R; Malek L; Horstkotte J; Baylacher M; Schwinger R; Rieber J; Mudra H; Hausleiter J; Huber K; Neumann FJ; Koltowski L; Huczek Z; Mehilli J; Massberg S;
    Thromb Haemost; 2017 Jan; 117(1):188-195. PubMed ID: 27652610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secondary prevention of acute coronary events with antiplatelet agents (SPACE-AA): One-year real-world effectiveness and safety cohort study in the French nationwide claims database.
    Blin P; Dureau-Pournin C; Benichou J; Bonello L; Dallongeville J; Danchin N; Falissard B; Thomas-Delecourt F; Jové J; Lassalle R; Droz C; Moore N
    Atherosclerosis; 2019 Feb; 281():98-106. PubMed ID: 30658197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.
    Aradi D; Komócsi A; Vorobcsuk A; Serebruany VL
    Thromb Haemost; 2013 Jan; 109(1):93-101. PubMed ID: 23197191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.